title: Prevention of restenosis by systemic drug therapy: back to the future?
authors.forename: Albert
authors.initials: A
authors.lastname: Schömig
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
authors.forename: Rainer
authors.initials: R
authors.lastname: Wessely
mesh_terms: D000077407:Cilostazol; D018849:Controlled Clinical Trials as Topic; D023903:Coronary Restenosis / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D000077205:Pioglitazone; D010919:Placebos; D015607:Stents / Q000009:adverse effects*; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
chemical_list: D005343:Fibrinolytic Agents; D010726:Phosphodiesterase Inhibitors; D010919:Placebos; D013777:Tetrazoles; D045162:Thiazolidinediones; D000077407:Cilostazol; D000077205:Pioglitazone